OncoMatch/Head & Neck Cancer (HNSCC)/PIK3CA
Head & Neck Cancer (HNSCC)PIK3CA Clinical Trials
PIK3CA mutations occur in approximately 15–20% of HNSCC and represent one of the few recurrently mutated targetable alterations in this cancer. PIK3CA mutations frequently co-occur with EGFR pathway alterations and HPV-positive oropharyngeal disease. Trials investigate alpha-selective PI3K inhibitors (alpelisib, taselisib), AKT inhibitors in PIK3CA/PTEN-altered HNSCC, and combinations with cetuximab or checkpoint immunotherapy.
Top recruiting PIK3CA Head & Neck Cancer (HNSCC) trials
Ranked by phase and US site count. See all 4 trials matched to your profile →
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Terremoto Biosciences Inc.
HTL0039732 in Participants With Advanced Solid Tumours
Cancer Research UK
A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With HR+ Breast Cancer and Other Select Solid Tumors
Totus Medicines
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
M.D. Anderson Cancer Center
Browse other molecular targets with active Head & Neck Cancer (HNSCC) trials.